3-异丁基-异噁唑-5-胺 | 1057064-36-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-异丁基-异噁唑-5-胺
• 英文名称: 3-isobutyl-isoxazol-5-ylamine
• 英文别名: 3-(2-Methylpropyl)-1,2-oxazol-5-amine
• CAS: 1057064-36-4
• 化学式: C₇H₁₂N₂O
• mdl: MFCD10692336
• 分子量: 140.185
• InChiKey: DZDIGBUGYPBFNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-异丁基-异噁唑-5-胺 在 吡啶 、 sodium hydroxide 、 丙酮 作用下， 生成 sulfanilic acid-(3-isobutyl-isoxazol-5-ylamide)
  参考文献：
  名称：

  Derivatives of 5-(amino-phenylsulfonamido)-isoxazoles

  摘要：

  公开号：

  US02555614A1
• 作为产物：
  描述：

  5-甲基-3-氧代己腈 在 硫酸羟胺 、 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 1.75h， 以90%的产率得到3-异丁基-异噁唑-5-胺
  参考文献：
  名称：

  A Reliable Synthesis of 3-Amino-5-Alkyl and 5-Amino-3-Alkyl Isoxazoles

  摘要：

  A reliable procedure that can be used to access a wide range of 3-amino-5-alkyl and 5-amino-3-alkyl isoxazoles was developed. Reaction temperature and pH were key factors that determined the regioselectivity of the two reactions.

  DOI：

  10.1055/s-0032-1317935

文献信息

• HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
  申请人：ARTMANN, III Gerald David

  公开号：US20120245187A1

  公开（公告）日：2012-09-27

  The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.

  本发明涉及一种新型有机化合物(I)及其在动物或人体治疗中的应用，包括含有化合物I的制药组合物以及利用化合物I制备用于治疗蛋白激酶依赖性疾病的制药组合物的应用，特别是在治疗增殖性疾病，如肿瘤疾病和眼部新生血管疾病方面的应用。
• Heterobicyclic Carboxamides as inhibitors for kinases
  申请人：Artmann, III Gerald David

  公开号：US20100168082A1

  公开（公告）日：2010-07-01

  The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.

  本发明涉及一种新型有机化合物(I)及其在动物或人体治疗中的应用，包括含有化合物I的药物组合物，以及利用化合物I制备用于治疗蛋白激酶依赖性疾病的药物组合物，特别是用于治疗增殖性疾病，如肿瘤疾病和眼部新生血管疾病的治疗。
• One-pot domino synthesis of five- and six-membered fused dihydropyridines promoted by PPh₃–NBS in aqueous medium
  作者：Bhanu Prasad Banda、Nagaraju Medishetti、Jagadeesh Babu Nanubolu、Krishnaiah Atmakur

  DOI：10.1039/d3ob00472d

  日期：——

  A facile one-pot synthesis of five- and six-membered fused dihydropyridines such as chromenodihydropyridines, pyrazolodihydropyridines and isoxazolopyridines was accomplished for the first time by employing PPh3–NBS via a formal [3 + 2 + 1] cycloaddition of 1,3-bisnucleophiles (i.e., 2-aminochromone, 4-aminochromone, 5-aminopyrazole and 5-aminoisoxazole), β-enaminones and aldehydes in aqueous medium

  首次使用 PPh 3 -NBS通过1,3-双亲核试剂（即2-氨基色酮、4-氨基色酮、5-氨基吡唑和 5-氨基异恶唑）、β-烯胺酮和水性介质中的醛。目前的方法涉及迈克尔型加成，然后进行分子内环化，从而形成两个新的 C-C 键和一个 C-N 键。高兼容性和优异的产量是该协议的优势。
• PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE
  申请人：Novartis AG

  公开号：EP2376478B1

  公开（公告）日：2017-04-19
• Metalloprotease inhibitors containing a squaramide moiety
  申请人：Gege Christian

  公开号：US20080221128A1

  公开（公告）日：2008-09-11

  The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.